Development of novel therapies for Huntington’s disease: hope and challenge
Abstract
Huntington’s disease (HD) is an autosomal dominant neurological disease. It is a
fatal neurological disorder affecting 5–10 out of 10 000 people. While there are
intensive research efforts focusing on uncovering molecular mechanisms of the
pathogenesis of HD, a number of studies have begun to look for effective therapies
for HD. There is a large body of encouraging news on novel therapeutic
developments. The present paper reviews drugs used for symptomatic treatment
of HD and experimental therapies targeting HD molecular pathology.
Keywords:
fatal neurological disorder affecting 5–10 out of 10 000 people. While there are
intensive research efforts focusing on uncovering molecular mechanisms of the
pathogenesis of HD, a number of studies have begun to look for effective therapies
for HD. There is a large body of encouraging news on novel therapeutic
developments. The present paper reviews drugs used for symptomatic treatment
of HD and experimental therapies targeting HD molecular pathology.